Eiger BioPharmaceuticals
![Eiger BioPharmaceuticals, hepatitis, lonafarnib, liver toxicity, phase 3 trial hold, pipeline, Clinical trial hold](https://pharmtales.com/wp-content/uploads/2023/09/Eiger-halts-hepatitis-drug-development-after-liver-toxicity-seeks-funding-for-other-programs.jpg)
Eiger halts hepatitis drug development after liver toxicity, seeks funding for other programs
Anika Sharma
Eiger BioPharmaceuticals has made the decision to discontinue the pursuit of a home for peginterferon lambda, a drug that was ...